Given Imaging, InScope partnership ends
Given Imaging has announced that InScope, a division of Ethicon Endo-Surgery, a Johnson & Johnson company, has ended its agreement to market and sell Given Imaging's PillCam ESO in the United States. InScope will pay $7.6 million in fees associated with the termination to the Jerusalem-based company.
The original agreement was signed in May 2004.
Ethicon Endo-Surgery cited a shift in its strategic priorities within gastroenterology and other areas as the reason for ending the relationship, according to a press release.
Given Imaging said that InScope will continue to support reimbursement activities for the PillCam ESO, maintain its market development field force for up to six months and has also agreed to continue to fund ongoing clinical trials associated with esophageal diseases.
Given Imaging received FDA clearance for the PillCam ESO in 2004 and for the PillCam ESO2 in 2007.
The original agreement was signed in May 2004.
Ethicon Endo-Surgery cited a shift in its strategic priorities within gastroenterology and other areas as the reason for ending the relationship, according to a press release.
Given Imaging said that InScope will continue to support reimbursement activities for the PillCam ESO, maintain its market development field force for up to six months and has also agreed to continue to fund ongoing clinical trials associated with esophageal diseases.
Given Imaging received FDA clearance for the PillCam ESO in 2004 and for the PillCam ESO2 in 2007.